| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.3M | +64.7% | +16.6% |
| Cost of Revenue | $1.4M | -58.2% | -12.1% |
| R&D Expense | $9.3M | -14.1% | +1.9% |
| SG&A Expense | $25.7M | +58.6% | +233.5% |
| Operating Income | -$33.1M | -16.9% | -112.6% |
| Net Income | -$32.0M | -13.2% | -125.2% |
| EPS (Basic) | -$3.59 |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $190.1M | +51.6% | +573.2% |
| Accounts Receivable | $3.5M | +50.0% | -13.3% |
| Current Assets | $208.1M | +45.0% | +311.7% |
| Total Assets | $252.4M | +34.7% | +165.8% |
| Current Liabilities | $21.0M | +10.3% | +38.5% |
| Long-term Debt |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$60.2M | — | — |
| Capital Expenditures | $1.5M | — | — |
| Investing Cash Flow | -$3.5M | — | — |
| Financing Cash Flow | $155.4M | — | — |
| Free Cash Flow | -$61.7M | — | — |
| +7.0% |
| -1460.9% |
| EPS (Diluted) | -$3.59 | +7.0% | -1460.9% |
| $8.7M |
| — |
| -7.5% |
| Total Liabilities | $21.3M | +10.0% | +2.5% |
| Stockholders' Equity | $231.1M | +37.6% | +211.5% |